No Data
Third Quarter Report 2024
Kexing Biopharm (688136.SH) released its performance for the first three quarters, with a net income of 17.18 million yuan, turning losses into profits year-on-year.
kexing biopharm (688136.SH) disclosed the third quarter report for 2024, with the company achieving revenue of 10...
Kexing Biopharm Gets UK Nod for Anti-Cancer Injection; Shares Rise 3%
Kexing Biopharm (688136.SH): Paclitaxel for Injection (Albumin Bound) obtains marketing authorization in the United Kingdom.
On October 17, kexing biopharm (688136.SH) announced that its partner, zhejiang Haichang Biomedical Technology Co., Ltd., recently received approval from the United Kingdom Medicines and Healthcare Products Regulatory Agency for the introduction of the product Apexelsin, a paclitaxel injection (albumin-bound) license. The paclitaxel injection (albumin-bound) formulation has clinical advantages compared to regular paclitaxel injections and paclitaxel liposomes, with improved safety and patient compliance, high clinical acceptance, and an indispensable role in the field of oncology treatment.
Kexing Biopharm Made Its Appearance at CPHI Milan 2024: Launch Ceremony for Apexelsin in EU Market Successfully Done
Insufficient Growth At Kexing Biopharm Co., Ltd. (SHSE:688136) Hampers Share Price
Revenues Working Against Shandong Kexing Bioproducts Co,.Ltd's (SHSE:688136) Share Price Following 26% Dive